JP2015516392A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516392A5 JP2015516392A5 JP2015505896A JP2015505896A JP2015516392A5 JP 2015516392 A5 JP2015516392 A5 JP 2015516392A5 JP 2015505896 A JP2015505896 A JP 2015505896A JP 2015505896 A JP2015505896 A JP 2015505896A JP 2015516392 A5 JP2015516392 A5 JP 2015516392A5
- Authority
- JP
- Japan
- Prior art keywords
- imidazo
- pyrazin
- phenylethyl
- pentan
- bromo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 78
- 210000002027 skeletal muscle Anatomy 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 45
- 229940125913 troponin activator Drugs 0.000 claims description 43
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 39
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 38
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 38
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 32
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 30
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 28
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 26
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 26
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 21
- -1 hexa-1-enyl Chemical group 0.000 claims description 19
- 210000003371 toe Anatomy 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 206010019280 Heart failures Diseases 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000001188 haloalkyl group Chemical group 0.000 claims description 8
- RSQGZEAXODVTOL-UHFFFAOYSA-N 5-ethynyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C#CC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 RSQGZEAXODVTOL-UHFFFAOYSA-N 0.000 claims description 7
- 208000030175 lameness Diseases 0.000 claims description 7
- 206010049565 Muscle fatigue Diseases 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 230000004220 muscle function Effects 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 2
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 239000002170 aldosterone antagonist Substances 0.000 claims description 2
- 229940083712 aldosterone antagonist Drugs 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 229940127218 antiplatelet drug Drugs 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 229960004195 carvedilol Drugs 0.000 claims description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 2
- 229960003009 clopidogrel Drugs 0.000 claims description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 229960005156 digoxin Drugs 0.000 claims description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical group C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 229960001208 eplerenone Drugs 0.000 claims description 2
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229960002237 metoprolol Drugs 0.000 claims description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229960002256 spironolactone Drugs 0.000 claims description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 2
- 239000011593 sulfur Chemical group 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 229960005001 ticlopidine Drugs 0.000 claims description 2
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims description 2
- SBJUQVUTJXSWQG-UHFFFAOYSA-N 5-ethenyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=CC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 SBJUQVUTJXSWQG-UHFFFAOYSA-N 0.000 claims 5
- SSZGBXHOXMJQIV-NSCUHMNNSA-N 3-(oxan-4-yl)-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(/C=C/C)=CN=C2N=C(O)N1C1CCOCC1 SSZGBXHOXMJQIV-NSCUHMNNSA-N 0.000 claims 4
- SSZGBXHOXMJQIV-IHWYPQMZSA-N 3-(oxan-4-yl)-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(\C=C/C)=CN=C2NC(=O)N1C1CCOCC1 SSZGBXHOXMJQIV-IHWYPQMZSA-N 0.000 claims 4
- NSPIDWPREXAAAQ-QHHAFSJGSA-N 3-cyclohexyl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(/C=C/C)=CN=C2NC(=O)N1C1CCCCC1 NSPIDWPREXAAAQ-QHHAFSJGSA-N 0.000 claims 4
- KUFBAWMESFZISC-NSCUHMNNSA-N 3-cyclopropyl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(/C=C/C)=CN=C2NC(=O)N1C1CC1 KUFBAWMESFZISC-NSCUHMNNSA-N 0.000 claims 4
- KUFBAWMESFZISC-IHWYPQMZSA-N 3-cyclopropyl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(\C=C/C)=CN=C2NC(=O)N1C1CC1 KUFBAWMESFZISC-IHWYPQMZSA-N 0.000 claims 4
- TUPQQYNBJJLKFQ-UHFFFAOYSA-N 3-pentan-3-yl-5-(trifluoromethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound FC(F)(F)C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 TUPQQYNBJJLKFQ-UHFFFAOYSA-N 0.000 claims 4
- WYRAXYZTIXGPNA-DAXSKMNVSA-N 3-pentan-3-yl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C\C=C/C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 WYRAXYZTIXGPNA-DAXSKMNVSA-N 0.000 claims 4
- ZUKQRELSXSZGNR-UHFFFAOYSA-N 3-pentan-3-yl-5-prop-1-en-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC(=C)C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 ZUKQRELSXSZGNR-UHFFFAOYSA-N 0.000 claims 4
- PFKZWBXZBQPWJI-SNAWJCMRSA-N 3-propan-2-yl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C\C=C\C1=CN=C2NC(=O)N(C(C)C)C2=N1 PFKZWBXZBQPWJI-SNAWJCMRSA-N 0.000 claims 4
- PFKZWBXZBQPWJI-PLNGDYQASA-N 3-propan-2-yl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C\C=C/C1=CN=C2N=C(O)N(C(C)C)C2=N1 PFKZWBXZBQPWJI-PLNGDYQASA-N 0.000 claims 4
- OOWPKYXJAWXXJL-UHFFFAOYSA-N 5-(dimethylamino)-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(N(C)C)N=C2N(C(CC)CC)C(O)=NC2=N1 OOWPKYXJAWXXJL-UHFFFAOYSA-N 0.000 claims 4
- XLKNITFKTUIDMX-UHFFFAOYSA-N 5-bromo-3-(2-methyl-1-morpholin-4-ylpropan-2-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=C(Br)N=C2N1C(C)(C)CN1CCOCC1 XLKNITFKTUIDMX-UHFFFAOYSA-N 0.000 claims 4
- JVUXJJNMSWDQNZ-MRVPVSSYSA-N 5-bromo-3-[(2r)-1-morpholin-4-ylpropan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@@H](C)N1C2=NC(Br)=CN=C2N=C1O)N1CCOCC1 JVUXJJNMSWDQNZ-MRVPVSSYSA-N 0.000 claims 4
- GMOWAKFCILZILA-GFCCVEGCSA-N 5-ethynyl-3-[(2r)-1-morpholin-4-ylbutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@@H](CC)N1C2=NC(=CN=C2N=C1O)C#C)N1CCOCC1 GMOWAKFCILZILA-GFCCVEGCSA-N 0.000 claims 4
- JCLOPOHRCQTTGK-UHFFFAOYSA-N 5-methoxy-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(OC)N=C2N(C(CC)CC)C(O)=NC2=N1 JCLOPOHRCQTTGK-UHFFFAOYSA-N 0.000 claims 4
- NSPIDWPREXAAAQ-KXFIGUGUSA-N 3-cyclohexyl-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(\C=C/C)=CN=C2NC(=O)N1C1CCCCC1 NSPIDWPREXAAAQ-KXFIGUGUSA-N 0.000 claims 3
- WYRAXYZTIXGPNA-QPJJXVBHSA-N 3-pentan-3-yl-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C/C=C/C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 WYRAXYZTIXGPNA-QPJJXVBHSA-N 0.000 claims 3
- RKWUIYMGQOAXEZ-UHFFFAOYSA-N 3-pentan-3-yl-5-prop-1-ynyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC#CC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 RKWUIYMGQOAXEZ-UHFFFAOYSA-N 0.000 claims 3
- WAXQRVPDPGLRKE-QMMMGPOBSA-N 5-bromo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical group C1([C@H](C)N2C(NC3=NC=C(Br)N=C32)=O)=CC=CC=C1 WAXQRVPDPGLRKE-QMMMGPOBSA-N 0.000 claims 3
- YHNUAFQPACGRHG-UHFFFAOYSA-N 2-(5-bromo-2-oxo-1h-imidazo[4,5-b]pyrazin-3-yl)butanoic acid Chemical compound C1=C(Br)N=C2N(C(C(O)=O)CC)C(O)=NC2=N1 YHNUAFQPACGRHG-UHFFFAOYSA-N 0.000 claims 2
- OEKBTLYYLIHXOZ-UHFFFAOYSA-N 2-oxo-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 OEKBTLYYLIHXOZ-UHFFFAOYSA-N 0.000 claims 2
- UPHGKXBLNGRTEU-VIFPVBQESA-N 2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carbonitrile Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C#N)=CC=CC=C1 UPHGKXBLNGRTEU-VIFPVBQESA-N 0.000 claims 2
- AUEBQUCREPKUBN-QMMMGPOBSA-N 2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxylic acid Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(O)=O)=CC=CC=C1 AUEBQUCREPKUBN-QMMMGPOBSA-N 0.000 claims 2
- BWMYZRWUZRHUKK-UHFFFAOYSA-N 2-oxo-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazine-5-carbonitrile Chemical compound C1=C(C#N)N=C2N(C(CC)CC)C(O)=NC2=N1 BWMYZRWUZRHUKK-UHFFFAOYSA-N 0.000 claims 2
- OIDUDOFDKDVFTB-UHFFFAOYSA-N 3-(1-aminobutan-2-yl)-5-bromo-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CN)CC)C(O)=NC2=N1 OIDUDOFDKDVFTB-UHFFFAOYSA-N 0.000 claims 2
- ZKELHGFJSAVRCZ-UHFFFAOYSA-N 3-(1-morpholin-4-ylbutan-2-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=CN=C2N1C(CC)CN1CCOCC1 ZKELHGFJSAVRCZ-UHFFFAOYSA-N 0.000 claims 2
- GXTJPCRFZLLAQY-VIFPVBQESA-N 3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=CN=C32)=O)=CC=CC=C1 GXTJPCRFZLLAQY-VIFPVBQESA-N 0.000 claims 2
- KMPZIANLLDHFPH-NSHDSACASA-N 3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]quinoxalin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC4=CC=CC=C4N=C32)=O)=CC=CC=C1 KMPZIANLLDHFPH-NSHDSACASA-N 0.000 claims 2
- FGVNKQWCHAKDRY-AWEZNQCLSA-N 3-[(1s)-1-phenylethyl]-5-(piperidin-1-ylmethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(CN4CCCCC4)N=C32)=O)=CC=CC=C1 FGVNKQWCHAKDRY-AWEZNQCLSA-N 0.000 claims 2
- SFDROONMRQVZOL-ZDUSSCGKSA-N 3-[(1s)-1-phenylethyl]-5-(piperidine-1-carbonyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)C(=O)N2CCCCC2)=O)=CC=CC=C1 SFDROONMRQVZOL-ZDUSSCGKSA-N 0.000 claims 2
- SYUYQEHWWBTQJK-UFVHFEBBSA-N 3-[(1s)-1-phenylethyl]-5-[(z)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)\C=C/C)=CC=CC=C1 SYUYQEHWWBTQJK-UFVHFEBBSA-N 0.000 claims 2
- HGXDYLNWUSYQKP-NSHDSACASA-N 3-[(1s)-1-phenylethyl]-5-propyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)CCC)=CC=CC=C1 HGXDYLNWUSYQKP-NSHDSACASA-N 0.000 claims 2
- FMCGTDCYKPWFQL-UHFFFAOYSA-N 3-benzyl-5-bromo-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1CC1=CC=CC=C1 FMCGTDCYKPWFQL-UHFFFAOYSA-N 0.000 claims 2
- GZESQDDXLPQCPD-UHFFFAOYSA-N 3-benzyl-5-methylsulfanyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(SC)=CN=C2NC(=O)N1CC1=CC=CC=C1 GZESQDDXLPQCPD-UHFFFAOYSA-N 0.000 claims 2
- QTFTVOGPJMOQQQ-UHFFFAOYSA-N 3-cyclohexyl-5-methylsulfanyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(SC)=CN=C2N=C(O)N1C1CCCCC1 QTFTVOGPJMOQQQ-UHFFFAOYSA-N 0.000 claims 2
- WJOZHHCMYYPKPL-UHFFFAOYSA-N 3-cyclopropyl-5-methylsulfanyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(SC)=CN=C2NC(=O)N1C1CC1 WJOZHHCMYYPKPL-UHFFFAOYSA-N 0.000 claims 2
- LJPNHODRROZMGG-UHFFFAOYSA-N 3-pentan-3-yl-1,4-dihydroimidazo[4,5-b]pyrazine-2,5-dione Chemical compound C1=C(O)N=C2N(C(CC)CC)C(O)=NC2=N1 LJPNHODRROZMGG-UHFFFAOYSA-N 0.000 claims 2
- OQTVWLOQVMHOME-UHFFFAOYSA-N 3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 OQTVWLOQVMHOME-UHFFFAOYSA-N 0.000 claims 2
- QWIGXPXZXMRYFN-UHFFFAOYSA-N 3-pentan-3-yl-1h-imidazo[4,5-b]quinoxalin-2-one Chemical compound C1=CC=C2N=C(NC(N3C(CC)CC)=O)C3=NC2=C1 QWIGXPXZXMRYFN-UHFFFAOYSA-N 0.000 claims 2
- WSZAYYDHFCRVMT-UHFFFAOYSA-N 3-pentan-3-yl-5-(2h-triazol-4-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1N=C2NC(=O)N(C(CC)CC)C2=NC=1C1=CNN=N1 WSZAYYDHFCRVMT-UHFFFAOYSA-N 0.000 claims 2
- LQLUETZNTCJOCT-UHFFFAOYSA-N 3-pentan-3-yl-5-propan-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC(C)C1=CN=C2NC(=O)N(C(CC)CC)C2=N1 LQLUETZNTCJOCT-UHFFFAOYSA-N 0.000 claims 2
- UEPSYMITWMMTTJ-UHFFFAOYSA-N 5-(1-methylpyrazol-4-yl)-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1N=C2NC(=O)N(C(CC)CC)C2=NC=1C=1C=NN(C)C=1 UEPSYMITWMMTTJ-UHFFFAOYSA-N 0.000 claims 2
- DXQMTYNFSGEMLQ-JTQLQIEISA-N 5-(2-hydroxypropan-2-yl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)C(C)(C)O)=O)=CC=CC=C1 DXQMTYNFSGEMLQ-JTQLQIEISA-N 0.000 claims 2
- JPWVZDIMURSFIS-LBPRGKRZSA-N 5-(2-methylprop-1-enyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(C=C(C)C)N=C32)=O)=CC=CC=C1 JPWVZDIMURSFIS-LBPRGKRZSA-N 0.000 claims 2
- NYEFRVNUSQHDBP-LBPRGKRZSA-N 5-(2-methylpropyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)CC(C)C)=CC=CC=C1 NYEFRVNUSQHDBP-LBPRGKRZSA-N 0.000 claims 2
- BYVOWOPGLJOQGT-ZDUSSCGKSA-N 5-(4-methylpiperazine-1-carbonyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(=O)N2CCN(C)CC2)=CC=CC=C1 BYVOWOPGLJOQGT-ZDUSSCGKSA-N 0.000 claims 2
- SUQDOUCHWLHPQX-ZDUSSCGKSA-N 5-(cyclohexen-1-yl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)C=2CCCCC=2)=O)=CC=CC=C1 SUQDOUCHWLHPQX-ZDUSSCGKSA-N 0.000 claims 2
- KCDSJTGZFUDLON-ZDUSSCGKSA-N 5-(morpholin-4-ylmethyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(CN4CCOCC4)N=C32)=O)=CC=CC=C1 KCDSJTGZFUDLON-ZDUSSCGKSA-N 0.000 claims 2
- SFPQZTPFSOQKEW-LBPRGKRZSA-N 5-(morpholine-4-carbonyl)-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(=O)N2CCOCC2)=CC=CC=C1 SFPQZTPFSOQKEW-LBPRGKRZSA-N 0.000 claims 2
- RIUFVPWKDKPVEE-AWEZNQCLSA-N 5-[(4-methylpiperazin-1-yl)methyl]-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(CN4CCN(C)CC4)N=C32)=O)=CC=CC=C1 RIUFVPWKDKPVEE-AWEZNQCLSA-N 0.000 claims 2
- LNSUVMJIGLAFPI-NSHDSACASA-N 5-[(dimethylamino)methyl]-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(CN(C)C)N=C32)=O)=CC=CC=C1 LNSUVMJIGLAFPI-NSHDSACASA-N 0.000 claims 2
- KXFYDWMMZNBTKB-UQYHUFHVSA-N 5-[(z)-hex-2-enyl]-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)C\C=C/CCC)=CC=CC=C1 KXFYDWMMZNBTKB-UQYHUFHVSA-N 0.000 claims 2
- ATHOGNKKHWAYKT-UHFFFAOYSA-N 5-acetyl-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound CC(=O)C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 ATHOGNKKHWAYKT-UHFFFAOYSA-N 0.000 claims 2
- LCZJTRRQEFNMEF-VIFPVBQESA-N 5-acetyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(C)=O)=CC=CC=C1 LCZJTRRQEFNMEF-VIFPVBQESA-N 0.000 claims 2
- NMFBGMYSYPALNO-UHFFFAOYSA-N 5-bromo-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2NC(=O)N(C(CC)CC)C2=N1 NMFBGMYSYPALNO-UHFFFAOYSA-N 0.000 claims 2
- HYRCCFZTXSFHMB-UHFFFAOYSA-N 5-bromo-3-(1,3-dihydroxypropan-2-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CO)CO)C(O)=NC2=N1 HYRCCFZTXSFHMB-UHFFFAOYSA-N 0.000 claims 2
- XPHYYSKGOGGPLD-UHFFFAOYSA-N 5-bromo-3-(1-methoxybutan-2-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N(C(COC)CC)C2=N1 XPHYYSKGOGGPLD-UHFFFAOYSA-N 0.000 claims 2
- UHVXLYLFBCPIBH-UHFFFAOYSA-N 5-bromo-3-(1-morpholin-4-yl-1-oxobutan-2-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=C(Br)N=C2N1C(CC)C(=O)N1CCOCC1 UHVXLYLFBCPIBH-UHFFFAOYSA-N 0.000 claims 2
- BKRHNTRJIUKUOI-UHFFFAOYSA-N 5-bromo-3-(2-morpholin-4-ylethyl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1CCN1CCOCC1 BKRHNTRJIUKUOI-UHFFFAOYSA-N 0.000 claims 2
- QFFFSTQFQPYCHG-UHFFFAOYSA-N 5-bromo-3-(oxan-4-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=C(Br)N=C2N1C1CCOCC1 QFFFSTQFQPYCHG-UHFFFAOYSA-N 0.000 claims 2
- WAXQRVPDPGLRKE-MRVPVSSYSA-N 5-bromo-3-[(1r)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@@H](C)N2C3=NC(Br)=CN=C3N=C2O)=CC=CC=C1 WAXQRVPDPGLRKE-MRVPVSSYSA-N 0.000 claims 2
- HRHMIFIUUCUENC-RXMQYKEDSA-N 5-bromo-3-[(2r)-1-hydroxybutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N([C@@H](CO)CC)C(O)=NC2=N1 HRHMIFIUUCUENC-RXMQYKEDSA-N 0.000 claims 2
- YQOCSKOMOMCTOF-SECBINFHSA-N 5-bromo-3-[(2r)-1-morpholin-4-ylbutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@@H](CC)N1C2=NC(Br)=CN=C2N=C1O)N1CCOCC1 YQOCSKOMOMCTOF-SECBINFHSA-N 0.000 claims 2
- HJHNPXSPMAXXDO-LLVKDONJSA-N 5-bromo-3-[(2r)-4-methyl-1-morpholin-4-ylpentan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@@H](CC(C)C)N1C2=NC(Br)=CN=C2N=C1O)N1CCOCC1 HJHNPXSPMAXXDO-LLVKDONJSA-N 0.000 claims 2
- UMUXBNQISPBMHB-RXMQYKEDSA-N 5-bromo-3-[(2r)-butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N([C@H](C)CC)C2=N1 UMUXBNQISPBMHB-RXMQYKEDSA-N 0.000 claims 2
- HRHMIFIUUCUENC-YFKPBYRVSA-N 5-bromo-3-[(2s)-1-hydroxybutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N([C@H](CO)CC)C2=N1 HRHMIFIUUCUENC-YFKPBYRVSA-N 0.000 claims 2
- YQOCSKOMOMCTOF-VIFPVBQESA-N 5-bromo-3-[(2s)-1-morpholin-4-ylbutan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@H](CC)N1C(NC2=NC=C(Br)N=C21)=O)N1CCOCC1 YQOCSKOMOMCTOF-VIFPVBQESA-N 0.000 claims 2
- JVUXJJNMSWDQNZ-QMMMGPOBSA-N 5-bromo-3-[(2s)-1-morpholin-4-ylpropan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C([C@H](C)N1C2=NC(Br)=CN=C2N=C1O)N1CCOCC1 JVUXJJNMSWDQNZ-QMMMGPOBSA-N 0.000 claims 2
- UMUXBNQISPBMHB-YFKPBYRVSA-N 5-bromo-3-[(2s)-butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N([C@@H](C)CC)C2=N1 UMUXBNQISPBMHB-YFKPBYRVSA-N 0.000 claims 2
- AOLADPNSDQMWQF-UHFFFAOYSA-N 5-bromo-3-[1-(4-methylsulfonylpiperazin-1-yl)butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1C(CC)CN1CCN(S(C)(=O)=O)CC1 AOLADPNSDQMWQF-UHFFFAOYSA-N 0.000 claims 2
- WDAYLXAGMDBEDY-UHFFFAOYSA-N 5-bromo-3-[1-(dimethylamino)butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CN(C)C)CC)C(O)=NC2=N1 WDAYLXAGMDBEDY-UHFFFAOYSA-N 0.000 claims 2
- CIEPWXIBLAGYFB-UHFFFAOYSA-N 5-bromo-3-[1-(methylamino)butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N(C(CNC)CC)C2=N1 CIEPWXIBLAGYFB-UHFFFAOYSA-N 0.000 claims 2
- ZTHFIYXLZKQTIZ-UHFFFAOYSA-N 5-bromo-3-cyclohexyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1C1CCCCC1 ZTHFIYXLZKQTIZ-UHFFFAOYSA-N 0.000 claims 2
- QZFCGAULXPKETL-UHFFFAOYSA-N 5-bromo-3-cyclopropyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(Br)=CN=C2NC(=O)N1C1CC1 QZFCGAULXPKETL-UHFFFAOYSA-N 0.000 claims 2
- DLGLLQCQYOSWFA-UHFFFAOYSA-N 5-bromo-3-heptan-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CCC)CCC)C(O)=NC2=N1 DLGLLQCQYOSWFA-UHFFFAOYSA-N 0.000 claims 2
- JMZLLOCPIPPQSP-UHFFFAOYSA-N 5-bromo-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(Br)N=C2N(C(CC)CC)C(O)=NC2=N1 JMZLLOCPIPPQSP-UHFFFAOYSA-N 0.000 claims 2
- RAGKXJIFFMBPQH-UHFFFAOYSA-N 5-bromo-3-propan-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N(C(C)C)C2=N1 RAGKXJIFFMBPQH-UHFFFAOYSA-N 0.000 claims 2
- SCOUYZQKEZNSSB-UHFFFAOYSA-N 5-bromo-3-tert-butyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound BrC1=CN=C2NC(=O)N(C(C)(C)C)C2=N1 SCOUYZQKEZNSSB-UHFFFAOYSA-N 0.000 claims 2
- WPDKEIHMTHBWTQ-UHFFFAOYSA-N 5-chloro-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound ClC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 WPDKEIHMTHBWTQ-UHFFFAOYSA-N 0.000 claims 2
- BFUPGUDOZHKGRY-ZDUSSCGKSA-N 5-cyclohexyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)C2CCCCC2)=O)=CC=CC=C1 BFUPGUDOZHKGRY-ZDUSSCGKSA-N 0.000 claims 2
- BQHUECBTWVGPTM-UHFFFAOYSA-N 5-cyclopropyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C=1N=C2NC(=O)N(C(CC)CC)C2=NC=1C1CC1 BQHUECBTWVGPTM-UHFFFAOYSA-N 0.000 claims 2
- MTWIPZQQMOGYOA-UHFFFAOYSA-N 5-ethenyl-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(C=C)N=C2NC(=O)N(C(CC)CC)C2=N1 MTWIPZQQMOGYOA-UHFFFAOYSA-N 0.000 claims 2
- NDZAPLNYXZLOQS-JTQLQIEISA-N 5-ethenyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(C=C)N=C32)=O)=CC=CC=C1 NDZAPLNYXZLOQS-JTQLQIEISA-N 0.000 claims 2
- AMMCGDYTUNTXNL-JTQLQIEISA-N 5-ethoxy-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)OCC)=CC=CC=C1 AMMCGDYTUNTXNL-JTQLQIEISA-N 0.000 claims 2
- BARVETZCMYVZCX-UHFFFAOYSA-N 5-ethyl-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound CCC1=CN=C2N(C(CC)CC)C(O)=NC2=N1 BARVETZCMYVZCX-UHFFFAOYSA-N 0.000 claims 2
- KIXVDSJCGANIHE-JTQLQIEISA-N 5-ethyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)CC)=CC=CC=C1 KIXVDSJCGANIHE-JTQLQIEISA-N 0.000 claims 2
- JPDFKESEFQRCBE-UHFFFAOYSA-N 5-ethyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CCC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 JPDFKESEFQRCBE-UHFFFAOYSA-N 0.000 claims 2
- HQJKFIVXLPPXQC-AWEZNQCLSA-N 5-hexyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)CCCCCC)=CC=CC=C1 HQJKFIVXLPPXQC-AWEZNQCLSA-N 0.000 claims 2
- POBMWJBUNZNVBG-VIFPVBQESA-N 5-methoxy-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)OC)=CC=CC=C1 POBMWJBUNZNVBG-VIFPVBQESA-N 0.000 claims 2
- UQASQCGBIPPBLD-UHFFFAOYSA-N 5-methyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1=C(C)N=C2N(C(CC)CC)C(O)=NC2=N1 UQASQCGBIPPBLD-UHFFFAOYSA-N 0.000 claims 2
- AUOSLRIENXAMHD-UHFFFAOYSA-N 5-methylsulfanyl-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazin-2-one Chemical compound CSC1=CN=C2N(C(CC)CC)C(O)=NC2=N1 AUOSLRIENXAMHD-UHFFFAOYSA-N 0.000 claims 2
- HDJDBIXLNJULNY-UHFFFAOYSA-N 5-methylsulfanyl-3-(oxan-4-yl)-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C12=NC(SC)=CN=C2NC(=O)N1C1CCOCC1 HDJDBIXLNJULNY-UHFFFAOYSA-N 0.000 claims 2
- JIEZRCLDDSWWHV-SECBINFHSA-N 5-methylsulfanyl-3-[(1r)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@@H](C)N2C(O)=NC3=NC=C(N=C32)SC)=CC=CC=C1 JIEZRCLDDSWWHV-SECBINFHSA-N 0.000 claims 2
- JIEZRCLDDSWWHV-VIFPVBQESA-N 5-methylsulfanyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)SC)=CC=CC=C1 JIEZRCLDDSWWHV-VIFPVBQESA-N 0.000 claims 2
- RCBUJATVMKPIKN-UHFFFAOYSA-N 5-methylsulfanyl-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CSC1=CN=C2NC(=O)N(C(CC)CC)C2=N1 RCBUJATVMKPIKN-UHFFFAOYSA-N 0.000 claims 2
- OWUGKZDHFBKQTR-UHFFFAOYSA-N 5-methylsulfanyl-3-propan-2-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound CSC1=CN=C2N=C(O)N(C(C)C)C2=N1 OWUGKZDHFBKQTR-UHFFFAOYSA-N 0.000 claims 2
- CXKKSQOGGIFLNS-BZEUWDEWSA-N 5-methylsulfinyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(NC3=NC=C(N=C32)S(C)=O)=O)=CC=CC=C1 CXKKSQOGGIFLNS-BZEUWDEWSA-N 0.000 claims 2
- HFHWCPSMUHVXBR-VIFPVBQESA-N 5-methylsulfonyl-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)S(C)(=O)=O)=CC=CC=C1 HFHWCPSMUHVXBR-VIFPVBQESA-N 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- ZEDPIMIYEJBDRX-UHFFFAOYSA-N methyl 2-oxo-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazine-5-carboxylate Chemical compound COC(=O)C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 ZEDPIMIYEJBDRX-UHFFFAOYSA-N 0.000 claims 2
- WIDYWXVZKVHDEZ-VIFPVBQESA-N methyl 2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxylate Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)C(=O)OC)=CC=CC=C1 WIDYWXVZKVHDEZ-VIFPVBQESA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- CFWJGEAWUINBDG-LBPRGKRZSA-N n,n-diethyl-2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)C(=O)N(CC)CC)=CC=CC=C1 CFWJGEAWUINBDG-LBPRGKRZSA-N 0.000 claims 2
- KCSLBARCQXBZTN-UHFFFAOYSA-N n,n-dimethyl-2-oxo-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound CN(C)C(=O)C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 KCSLBARCQXBZTN-UHFFFAOYSA-N 0.000 claims 2
- WFUAIWYQPBEHLA-JTQLQIEISA-N n,n-dimethyl-2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(=O)N(C)C)=CC=CC=C1 WFUAIWYQPBEHLA-JTQLQIEISA-N 0.000 claims 2
- SKZMEPYTEPEEQK-AWEZNQCLSA-N n-benzyl-2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(=O)NCC=2C=CC=CC=2)=CC=CC=C1 SKZMEPYTEPEEQK-AWEZNQCLSA-N 0.000 claims 2
- NAPPLGJAEMHOAG-UHFFFAOYSA-N n-methyl-2-oxo-1-pentan-3-yl-3h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound CNC(=O)C1=CN=C2N(C(CC)CC)C(O)=NC2=N1 NAPPLGJAEMHOAG-UHFFFAOYSA-N 0.000 claims 2
- QYQZBGDQEVAJKO-VIFPVBQESA-N n-methyl-2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C(O)=NC3=NC=C(N=C32)C(=O)NC)=CC=CC=C1 QYQZBGDQEVAJKO-VIFPVBQESA-N 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 2
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- AKWIAIDKXNKXDI-UHFFFAOYSA-N 1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=CNC=1 AKWIAIDKXNKXDI-UHFFFAOYSA-N 0.000 claims 1
- FAICLJXBBVXJHR-QMMMGPOBSA-N 2-oxo-3-[(1s)-1-phenylethyl]-1h-imidazo[4,5-b]pyrazine-5-carboxamide Chemical compound C1([C@H](C)N2C3=NC(=CN=C3N=C2O)C(N)=O)=CC=CC=C1 FAICLJXBBVXJHR-QMMMGPOBSA-N 0.000 claims 1
- SSZWKKQDZMVWCW-UHFFFAOYSA-N 3,5,6-trimethyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical group N1=C(C)C(C)=NC2=C1N(C)C(=O)N2 SSZWKKQDZMVWCW-UHFFFAOYSA-N 0.000 claims 1
- SYUYQEHWWBTQJK-KTROKBFUSA-N 3-[(1s)-1-phenylethyl]-5-[(e)-prop-1-enyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound C1([C@H](C)N2C(=O)NC3=NC=C(N=C32)/C=C/C)=CC=CC=C1 SYUYQEHWWBTQJK-KTROKBFUSA-N 0.000 claims 1
- DGXUBNJTSDKMNH-UHFFFAOYSA-N 3-[2-[[3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl]methylamino]pyrimidin-5-yl]benzamide Chemical group NC(=O)C1=CC=CC(C=2C=NC(NCC3(CC(F)C3)C=3C(=CC=CN=3)F)=NC=2)=C1 DGXUBNJTSDKMNH-UHFFFAOYSA-N 0.000 claims 1
- VGMPXCLEQITWTP-UHFFFAOYSA-N 3-methyl-1h-imidazo[4,5-b]pyrazin-2-one Chemical group C1=CN=C2NC(=O)N(C)C2=N1 VGMPXCLEQITWTP-UHFFFAOYSA-N 0.000 claims 1
- AEUJTZJJOJMFJG-UHFFFAOYSA-N 3-piperidin-4-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound O=C1NC2=NC=CN=C2N1C1CCNCC1 AEUJTZJJOJMFJG-UHFFFAOYSA-N 0.000 claims 1
- XGYMKEPKOZVQSB-UHFFFAOYSA-N 5-(hydroxymethyl)-1,6-dimethyl-3h-imidazo[4,5-b]pyrazin-2-one Chemical group N1=C(CO)C(C)=NC2=C1NC(=O)N2C XGYMKEPKOZVQSB-UHFFFAOYSA-N 0.000 claims 1
- QZCBPABKXFZXCW-UHFFFAOYSA-N 5-[2-(2-oxo-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-5-yl)ethynyl]-3-pentan-3-yl-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound N1=C2NC(=O)N(C(CC)CC)C2=NC(C#CC2=CN=C3N=C(O)N(C3=N2)C(CC)CC)=C1 QZCBPABKXFZXCW-UHFFFAOYSA-N 0.000 claims 1
- QUCSBNPOJMPNDS-UHFFFAOYSA-N 5-bromo-3-[(3-nitrophenyl)methyl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical group [O-][N+](=O)C1=CC=CC(CN2C(NC3=NC=C(Br)N=C32)=O)=C1 QUCSBNPOJMPNDS-UHFFFAOYSA-N 0.000 claims 1
- DZHHDFNQNKJYQE-UHFFFAOYSA-N 5-bromo-3-[1-(4-methylpiperazin-1-yl)butan-2-yl]-1h-imidazo[4,5-b]pyrazin-2-one Chemical compound OC1=NC2=NC=C(Br)N=C2N1C(CC)CN1CCN(C)CC1 DZHHDFNQNKJYQE-UHFFFAOYSA-N 0.000 claims 1
- CHJDFFWYGFUOHU-UHFFFAOYSA-N C(=CC)N1C(=NC=2C1=NC=CN=2)O Chemical compound C(=CC)N1C(=NC=2C1=NC=CN=2)O CHJDFFWYGFUOHU-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 210000002683 foot Anatomy 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims 1
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 238000010626 work up procedure Methods 0.000 claims 1
- 0 **c1c(*)nc(N(*)*)nc1* Chemical compound **c1c(*)nc(N(*)*)nc1* 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623003P | 2012-04-11 | 2012-04-11 | |
| US61/623,003 | 2012-04-11 | ||
| US201261646842P | 2012-05-14 | 2012-05-14 | |
| US61/646,842 | 2012-05-14 | ||
| US201261693061P | 2012-08-24 | 2012-08-24 | |
| US61/693,061 | 2012-08-24 | ||
| US201261735809P | 2012-12-11 | 2012-12-11 | |
| US61/735,809 | 2012-12-11 | ||
| PCT/US2013/036114 WO2013155262A2 (en) | 2012-04-11 | 2013-04-11 | Methods for improving resistance to skeletal muscle fatigue |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017253312A Division JP6535727B2 (ja) | 2012-04-11 | 2017-12-28 | 骨格筋疲労に対する耐性を向上させるための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516392A JP2015516392A (ja) | 2015-06-11 |
| JP2015516392A5 true JP2015516392A5 (enExample) | 2016-06-09 |
| JP6352244B2 JP6352244B2 (ja) | 2018-07-04 |
Family
ID=49328282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505896A Expired - Fee Related JP6352244B2 (ja) | 2012-04-11 | 2013-04-11 | 骨格筋疲労に対する耐性を向上させるための方法 |
| JP2017253312A Expired - Fee Related JP6535727B2 (ja) | 2012-04-11 | 2017-12-28 | 骨格筋疲労に対する耐性を向上させるための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017253312A Expired - Fee Related JP6535727B2 (ja) | 2012-04-11 | 2017-12-28 | 骨格筋疲労に対する耐性を向上させるための方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150250784A1 (enExample) |
| EP (1) | EP2836590A4 (enExample) |
| JP (2) | JP6352244B2 (enExample) |
| KR (1) | KR102163931B1 (enExample) |
| CN (2) | CN104395458A (enExample) |
| AU (3) | AU2013245917A1 (enExample) |
| BR (1) | BR112014025251B1 (enExample) |
| CA (1) | CA2869675C (enExample) |
| EA (1) | EA032480B1 (enExample) |
| HK (1) | HK1206389A1 (enExample) |
| IL (2) | IL234886A (enExample) |
| MX (1) | MX2014012179A (enExample) |
| PH (1) | PH12014502286B1 (enExample) |
| SG (2) | SG11201406359TA (enExample) |
| WO (1) | WO2013155262A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| WO2013010015A2 (en) | 2011-07-13 | 2013-01-17 | Cytokinetics, Inc. | Combination als therapy |
| WO2014141104A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| EP3137622B1 (en) * | 2014-04-29 | 2021-11-24 | Cytokinetics, Inc. | Methods of reducing decline in vital capacity |
| MX389591B (es) | 2014-08-29 | 2025-03-20 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA |
| ES2750751T3 (es) * | 2014-09-09 | 2020-03-27 | Astellas Pharma Inc | Composición farmacéutica novedosa para la prevención y/o el tratamiento de la incontinencia urinaria |
| SMT202200201T1 (it) | 2016-02-12 | 2022-07-21 | Cytokinetics Inc | Derivati di tetraidroisochinolina |
| BR112019000589A2 (pt) | 2016-07-14 | 2019-04-24 | Pfizer Inc. | pirimidina carboxamidas como inibidores da enzima vanina-1 |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| KR20220038056A (ko) | 2019-07-23 | 2022-03-25 | 아모피컬 리미티드 | 운동 수행능력을 개선시키기 위한 비정질 탄산칼슘 |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| JP7825618B2 (ja) | 2020-11-06 | 2026-03-06 | サイトキネティックス， インコーポレイテッド | 二環式１，４－ジアゼパノン及びその治療的使用 |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005139081A (ja) * | 2003-11-04 | 2005-06-02 | Takada Seiyaku Kk | ビントペロール含有製剤 |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| US8299248B2 (en) * | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| SI2583970T1 (sl) * | 2006-08-02 | 2016-03-31 | Cytokinetics, Inc. | Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine |
| MX2010008518A (es) * | 2008-02-04 | 2010-11-10 | Cytokinetics Inc | Ciertas entidades quimicas, composiciones y metodos. |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AU2013243671B2 (en) * | 2012-04-02 | 2017-09-21 | Cytokinetics, Inc. | Methods for improving diaphragm function |
-
2013
- 2013-04-11 CN CN201380019567.7A patent/CN104395458A/zh active Pending
- 2013-04-11 US US14/391,087 patent/US20150250784A1/en not_active Abandoned
- 2013-04-11 BR BR112014025251-3A patent/BR112014025251B1/pt not_active IP Right Cessation
- 2013-04-11 WO PCT/US2013/036114 patent/WO2013155262A2/en not_active Ceased
- 2013-04-11 KR KR1020147028128A patent/KR102163931B1/ko not_active Expired - Fee Related
- 2013-04-11 SG SG11201406359TA patent/SG11201406359TA/en unknown
- 2013-04-11 CA CA2869675A patent/CA2869675C/en active Active
- 2013-04-11 SG SG10201704166RA patent/SG10201704166RA/en unknown
- 2013-04-11 MX MX2014012179A patent/MX2014012179A/es unknown
- 2013-04-11 AU AU2013245917A patent/AU2013245917A1/en not_active Abandoned
- 2013-04-11 EA EA201491666A patent/EA032480B1/ru not_active IP Right Cessation
- 2013-04-11 CN CN202010369880.5A patent/CN111840294A/zh active Pending
- 2013-04-11 EP EP13775275.4A patent/EP2836590A4/en not_active Ceased
- 2013-04-11 JP JP2015505896A patent/JP6352244B2/ja not_active Expired - Fee Related
- 2013-04-11 HK HK15106995.5A patent/HK1206389A1/xx unknown
-
2014
- 2014-09-29 IL IL234886A patent/IL234886A/en active IP Right Grant
- 2014-10-10 PH PH12014502286A patent/PH12014502286B1/en unknown
-
2017
- 2017-02-06 IL IL250473A patent/IL250473A0/en unknown
- 2017-12-28 JP JP2017253312A patent/JP6535727B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-08 AU AU2018200930A patent/AU2018200930A1/en not_active Abandoned
- 2018-11-30 US US16/206,747 patent/US20190167676A1/en not_active Abandoned
-
2019
- 2019-11-22 AU AU2019268177A patent/AU2019268177A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516392A5 (enExample) | ||
| Versmissen et al. | Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension | |
| AU2017232162B2 (en) | Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer | |
| JP6535727B2 (ja) | 骨格筋疲労に対する耐性を向上させるための方法 | |
| JP2012514631A5 (enExample) | ||
| CN113474337A (zh) | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 | |
| KR20140040715A (ko) | 신경계 장애 및 암의 치료를 위한 8-에틸-6-(아릴)피리도[2,3-ｄ]피리미딘-7(8ｈ)-온 | |
| JP2016538313A5 (enExample) | ||
| HRP20220619T1 (hr) | Postupci za liječenje ar+ raka dojke | |
| JP2018515613A (ja) | 癌を治療するための白金含有抗腫瘍剤とジアンヒドロガラクチトールの類縁体又は誘導体の組み合わせ | |
| JP2015526410A5 (enExample) | ||
| AU2016231259A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| JP2020500190A (ja) | ＨＤＭ２−ｐ５３相互作用阻害剤の用量およびレジメン | |
| CA2793616A1 (en) | New combination therapy in treatment of oncological and fibrotic diseases | |
| JP2018512403A5 (enExample) | ||
| CA2978807A1 (en) | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines | |
| JP2018534259A5 (enExample) | ||
| JP2017535600A5 (enExample) | ||
| CA2611474A1 (en) | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor | |
| WO2016193955A1 (en) | Combinations of kinase inhibitors for treating colorectal cancer | |
| BRPI0612076A2 (pt) | modulação sinergìstica de flt3 cinase empregando-se moduladores de aminopirimidinas cinase | |
| Chen et al. | AMG 580: A novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer | |
| WO2019180141A1 (en) | Combinations of rogaratinib | |
| JP2017536397A (ja) | 線維症の治療方法 | |
| AR108501A2 (es) | Compuesto de imidazo[4,5-b]pirazin-2-ol sustituido o un compuesto de 1h-imidazo[4,5-b]pirazin-2(3h)-ona sustituido, composición farmacéutica que lo comprende y su uso para preparar un medicamento |